Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (October 2018)
29 slides from Inspiremd's investor presentation, Oct 9, 2018
Slide 1: InspireMD – October 2018
inspireliD NYSE MKT: NSPR I OCTOBER 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” "will," plans," "expects," "anticipates," “projects,” "predicts," “estimates,” "aims," "believes," "hopes," “potential” or similar words. Forward-looking
Slide 3: About InspireMD
About InspireMD InspireMD is a commercial-stage medical device company developing and marketing innovative embolic prevention systems (EPS) that can prevent harmful consequences, with a primary focus on preventing stroke in patients with carotid artery disease (CAD) COMPANY TECHNOLOGY Proprietary Mi
Slide 4: Company Highlights
Company Highlights Lead product, CGuard™ EPS Benefits demonstrated in multiple trials Commercial-stage with accelerating sales growth $1bn+ global market opportunity Capital Structure Strong IP franchise A potential paradigm shift in the treatment of carotid artery disease and stroke prevention High
Slide 5: Leadership
Leadership Significant track records of success es Bar Boston [Pfizer President and CEO Scientific Craig Shore > mm Paul Stuk: ge, Michael Berman Boston 5 . Scientific a a LUTON. eemeeennreee MO: ObeartFiow Cordis. RB ARVaRD Thomas Kester A) A Kester Search Group? AN rama Sol B: Ph eae G~ TZ Special
Slide 6: Stroke is the Second Biggest Cause of Death
Stroke is the Second Biggest Cause of Death An estimated 15 million people suffer from stroke annually? Top 10 Causes of Death Globally, 2016 ¢ 5.7 million deaths! ¢« 5 million people left permanently disabled 0] * $34 billion associated with stroke management in the US alone? mischaemic Heart Disea
Slide 7: Stroke Prevalence Increasing Among Young People
Stroke Prevalence Increasing Among Young People Between 1990 and 2013, there was a Global Prevalence of Ischemic Stroke, Aged 20 — 64 significant increase in the global prevalence of ischemic stroke among 8 Ts young people aged 20-64 7 Approximately 85% of all strokes are ischemic strokes, which res
Slide 8: Unmet Need: A Safer Technology for Stroke Prevention in CAD
Unmet Need: A Safer Technology for Stroke Prevention in CAD Surgery vs. Carotid Artery Stenting Carotid Endarterectomy (CEA) Filter Protected Stenting (CAS) Low stroke risk’, but... Patient friendly, long-term durability’, Invasive; risk of surgical complications Non-Invasive; risk of complications
Slide 9: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents, depending on plaque morphology/symptomatic status and stent type. The consequence is cerebral embolization, either directly or via additional thrombus formation.
Slide 10: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke ocedure Post-intervention showing successful opening of the occluded carotid artery with conventional stenting and an MRI showing multiple micro-infarcts (obstructions) post- procedure due to liberation of embolic particles. Pre-intervention sho
Slide 11: A Billion Dollar Market Opportunity
A Billion Dollar Market Opportunity Carotid procedures today are primarily surgical Carotid procedures tomorrow could be mostly minimally invasive with Cguard™ 20% of Market »> 80% 100% of Market of Market mCEA mCAS CAS MicroNet™ covered stents could become the Gold Standard 2.2M diagnosed with caro
Slide 12: A Billion Dollar Market Opportunity
A Billion Dollar Market Opportunity Carotid procedures today are primarily surgical Carotid procedures tomorrow could be mostly minimally invasive with Cguard™ 20% of Market »> 80% 100% of Market of Market mCEA mCAS CAS MicroNet™ covered stents could become the Gold Standard 2.2M diagnosed with caro
Slide 13: The InspireMD Solution: CGuard EPS
The InspireMD Solution: CGuard™ EPS No plaque coverage - leading to plaque protrusions or The MicroNetTM permanently covers plaque and prolapse passing into the vessel lumen prevents “debris” from passing through the mesh. Conventional Stent CGuard™ TM EPS jet mesh preventing prolapse Yoshimura, et
Slide 14: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience CARENET Clinical Trial (2014) 30 Patient Safety and Efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical
Slide 15: Independent Clinical Validation
Independent Clinical Validation Independent study conducted in 30 patients with internal carotid artery disease Clinical results (2016) * 100% success in implanting the CGuard™ EPS + No peri- or post-procedural complications + No deaths, major adverse events, minor or major strokes, or new neurologi
Slide 16: Independent Clinical Validation (continued)
Independent Clinical Validation (continued) The lron-Guard Registry + Physician initiated * 12 large Italian medical centers + 200 patients | | N (Ss a Clinical Results * 100% success in implanting the CGuard EPS “The IRON-Guard Registry shows promising results in this interim + No major adverse cer
Slide 17: CGuard vs Conventional Stents and Surgery MACCE results
CGuard™ vs Conventional Stents and Surgery 30 day MACCE results (Major and Minor Adverse Cardiac and Cerebral Events) ¢ CGuard™ has a superior profile versus historical data on both carotid stents and 800% ou 5.20% (3) surgery 200% =e CGuard™ is a next-generation stent ee supported by a strong and g
Slide 18: A Leading Vascular Surgeon's View
A Leading Vascular Surgeon’s View re) “The CGuard™, in comparison to other [carotid] stents, even in comparison to other mesh covered stents, is a very easy to use device. Very simple, you take it off the shelf and you use it and that’s it.” “Patient risks associated with stenting using CGuard™ are
Slide 19: CGuard - Accelerating Sales Growth
CGuard™ - Accelerating Sales Growth Growth continues to accelerate for 2018/2017 Year End Sales in USD Half Year Sales in USD 2,500,000 1,400,000 1,200,000 2,000,000 922,000 ; 68% Growth qaatON — 1,500,000 Sr soon 789,000- 1,147,000" 1,000,000 600,000 400,000 500,000 200,000 0) 0 Year End 2016 Year
Slide 20: Accelerating CGuard Sales Growth: Italy
Accelerating CGuard™ Sales Growth: Italy 600,000 500,000 400,000 300,000 - 200,000 Italy CGuard sales in USD 229,000 556,000 100,000 2015 2016 2017 450,000 400,000 - 350,000 - 300,000 - 250,000 200,000 150,000 100,000 50,000 0 Italy First Half 2017 and 2018 CGuard sales in USD 393,000 33,000. First
Slide 21: Accelerating CGuard Sales Growth: Germany
Accelerating CGuard™ Sales Growth: Germany New Distributor in Q2 2017 Growth Trend is accelerating ° 500,000 450,000 400,000 350,000 300,000 250,000 200,000 150,000 100,000 50,000 le) Half Year Sales in USD 435,000 | sxc Growth i 265,000" Second Half 2017 First Half 2018 InspireMD October 2018 | 21
Slide 22: Addressable Stroke Prevention Device Market
Addressable Stroke Prevention Device Market 3) IQ % IQ 7 O. O- O O: 0. 13mn people 2.2mn people ~600,000 received Untapped market: Plus roughly globally with high with HGS surgical/stent At least 1.6mn 10mn people who giederearotd diagnosed treatment patients could be are undiagnosed stenosis (HGS)
Slide 23: Commercial Strategy
Commercial Strategy Transition current users of conventional carotid stents to CGuardTM Communication of CGuard™ clinical data Continue to support investigator initiated clinical registries Engage advisory board, further develop network of KOLs, establish centers of excellence Expand footprint in ex
Slide 24: CGuard Product Development
CGuard™ Product Development Next generation CGuard™ -5 French CGuard™ Evaluating synergistic opportunities Pre-IDE FDA submission for CGuard™ February 2017 Formal FDA meeting held April 2017 9 months of pre-clinical work required to file IDE application to begin a US clinical trial Minimally invasiv
Slide 25: Recent/Upcoming Anticipated Milestones
Recent/Upcoming Anticipated Milestones Continued clinical trial/registry results CGuard approval and CGuard approval in 5 French CGuard™ launch in Mexico Brazil and Australia submission H12018 H22018 H12019 H22019 MID2019 H22019 Establish Centers of Partnership in Major Asia CGuard U.S. IDE Excellen
Slide 26: Intellectual Property Portfolio
Intellectual Property Portfolio PATENT RIGHTS ISSUED ALLOWED PENDING USA 8 3 9 Rest of World 35 2 19 Proprietary platform technology supported by a robust intellectual property portfolio Continue to strengthen and broaden patent protection globally to enable future pipeline products inspireMD Octobe
Slide 27: Summary Financials
Summary Financials NYSE AMER NSPR Stock Price (10/5/18): $0.27 Average three month daily trading volume: 3.4M Shares outstanding (10/5/18): 37.0M Shares Outstanding Including full conversion of preferred shares and prefunded warrants 447M (10/5/2018): Market Capitalization including full conversion
Slide 28: Summary
Summary Q SQ ey — tH Focused on the deadly and catastrophic problem of stroke that is estimated to cost the healthcare system more than $34BB annually in the US alone The current addressable market for CGuard ™ EPS is estimated to be $1BB with the potential to further expand into the 1.6MM patient p
Slide 29: James Barry, Ph.D., President and CEO; Craig Shore, CFO
James Barry, Ph.D., President and CEO Craig Shore, CFO inspireMD 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com